Abstract: The present invention provides a locking method and system, and the method includes: a locking system performing a phase discrimination and conversion process to an input signal Fi of an external standard source and a feedback output signal F0 of a local thermostatic crystal oscillator which pass through a frequency division, to generate a clock signal clk and a signal sign which is used to denote a frequency size relationship between the signal Fi and the signal F0, and performing a filtering process to the signal clk and the signal sign, and performing a voltage controlled oscillation process to a signal ahead used to denote that the frequency of the signal F0 is lower than the frequency of the signal Fi and a signal lag used to denote that the frequency of the signal F0 is higher than the frequency of the signal Fi, to implement a locking of the signal F0 and the signal Fi.

Abstract: The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in individuals with mild osteoarthritis as compared with individuals without osteoarthritis. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in diagnosing mild osteoarthritis. Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and/or selectively hybridize to the product of the biomarkers of the invention to monitor disease regression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis.

Abstract: The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof. In some aspects, the invention provides methods and compositions for treating CNS-related disorders.

Abstract: The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in individuals with mild osteoarthritis as compared with individuals without osteoarthritis. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in diagnosing mild osteoarthritis. Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and/or selectively hybridize to the product of the biomarkers of the invention to monitor disease regression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis.

Abstract: A peelable light conversion luminescent film consisting of a substrate and a light conversion coating layer thereon is provided. The light conversion coating layer consists of a fluorescent material, a two-component silicone resin, a diluent and an adjuvant. The substrate is a fluorine-containing polyester film which can be easily peeled off from the light conversion coating layer when using the light conversion film. The fluorine-containing polyester film can function as a substrate and as a protective film. The fluorine-containing polyester film can be easily peeled off to avoid the deformation of light conversion coating layer. After the peeling off from the fluorine-containing polyester film, the light refraction is reduced and the luminescent efficiency is increased.

Abstract: The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in osteoarthritis and/or in a particular stage of osteoarthritis, as well as a means of selecting the novel biomarker combinations. The measurement of expression of the products of the biomarkers and combinations of biomarkers demonstrates particular advantage in one or more of the following: (a) diagnosing individuals as having arthritis, (b) differentiating between two stages of osteoarthritis (OA) and (c) diagnosing individuals as having a particular stage of OA. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers are within the scope of the invention as are kits containing said polynucleotides and proteins and the use of said polynucleotides and proteins.

Abstract: In one aspect the invention is a method of testing for one or more colorectal pathologies or one or more subtypes of colorectal pathology (in one embodiment colorectal cancer) in a test individual by providing data corresponding to a level of products of selected biomarkers and applying the data to a formula to provide an indication of whether the test individual has one or more colorectal pathologies or one or more subtypes of colorectal pathology. In some aspects the method is computer based and a computer applies the data to the formula. Also encompassed are kits for measuring data corresponding to the products of selected biomarkers which in some embodiments include a computer readable medium. Also encompassed are kits and methods of monitoring therapeutic efficacy of treatments for one or more colorectal pathologies.

Abstract: A method for preventing the wear of monocrystalline diamond tools by applying multiple physical fields during ultra-precision machining is disclosed, wherein dislocation form of lower energy state will appear by applying different physical fields such as electric field, magnetic field and laser irradiation around the diamond tool so as to change the construction of crystal interface and interfacial energy.

Abstract: The present invention provides a locking method and system, and the method includes: a locking system performing a phase discrimination and conversion process to an input signal Fi of an external standard source and a feedback output signal F0 of a local thermostatic crystal oscillator which pass through a frequency division, to generate a clock signal clk and a signal sign which is used to denote a frequency size relationship between the signal Fi and the signal F0, and performing a filtering process to the signal clk and the signal sign, and performing a voltage controlled oscillation process to a signal ahead used to denote that the frequency of the signal F0 is lower than the frequency of the signal Fi and a signal lag used to denote that the frequency of the signal F0 is higher than the frequency of the signal Fi, to implement a locking of the signal F0 and the signal Fi.

Abstract: Disclosed is a method of testing for colorectal cancer in a test individual by providing data corresponding to a level of products of selected biomarkers and applying the data to a formula to provide an indication of whether the test individual has colorectal cancer. Also disclosed are kits for measuring data corresponding to the products of selected biomarkers, and kits and methods of monitoring therapeutic efficacy of treatments for colorectal cancer.

Abstract: In one aspect the invention is a method of testing for one or more colorectal pathologies or one or more subtypes of colorectal pathology (in one embodiment colorectal cancer) in a test individual by providing data corresponding to a level of products of selected biomarkers and applying the data to a formula to provide an indication of whether the test individual has one or more colorectal pathologies or one or more subtypes of colorectal pathology. In some aspects the method is computer based and a computer applies the data to the formula. In other aspects a computer system is configured with instructions that cause the processor to provide a user with the indication of whether the test individual has colorectal pathology. Also encompassed are kits for measuring data corresponding to the products of selected biomarkers which in some embodiments include a computer readable medium. Also encompassed are kits and methods of monitoring therapeutic efficacy of treatments for one or more colorectal pathologies.

Abstract: The present invention provides blue-green silicate luminescent materials, which are rare earth activated alkaline-earth metals silicates having a formula of Ba1-bMbSi2O(5-a/2)Da:Eux, Lny, wherein M is one or two elements selected from the group consisting of Mg, Ca and Sr; D is one or two ions selected from the group consisting of Cl? and F?; Ln is an ion selected from Ce, Er, Pr or Mn; a, b, x, and y are molar coefficients and within following ranges: 0?a<2, 0?b<0.5, 0<x<1, 0?y<0.5. the blue-green silicate luminescent material can be excited by UV, violet and blue lights of 200 nm-450 nm and emit blue-green light with a peak wavelength of around 490-510 nm. The luminescent materials can be used not only in color-rendering index adjustment of tricolor lamps and white-light LED, but also in decoration and lighting with special colors.

Abstract: The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in osteoarthritis and/or in a particular stage of osteoarthritis, as well as a means of selecting the novel biomarker combinations. The measurement of expression of the products of the biomarkers and combinations of biomarkers demonstrates particular advantage in one or more of the following: (a) diagnosing individuals as having arthritis, (b) differentiating between two stages of osteoarthritis (OA) and (c) diagnosing individuals as having a particular stage of OA. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers are within the scope of the invention as are kits containing the polynucleotides and proteins and the use of the polynucleotides and proteins.

Abstract: The invention provides a waterproof self-luminescent spray-painted film with a thickness of 0.150-1.560 mm. The film has, from top to bottom, ink reception layer (1), connection layer (2) and light-storing photo-luminescent film (3); wherein the ink reception layer (1) is prepared by mixing inorganic filler, adhesive, color fixing agent, coupling agent, surfactant, cross-linking agent, fluorescent whitening agent and water at a ratio. The film has good waterproof property, rapid ink-drying, clear image after being ink-jet printed, and high color density. The film is self-luminescent after absorbing external visible light, and is visible and has the illumination function of low lighting intensity in darkness after a pattern or character is printed on the surface of the film. The film can be widely used in various occasions, such as home decoration, hotels, corridors, office buildings, cinemas, warehouses, ship cabins, underpasses and the places in need of large scale printing and high-precision patterns.

Abstract: The invention relates to the identification and selection of sequences which demonstrate particular advantage in identifying individuals having osteoarthritis (OA). The invention also provides a selection of sequences particularly useful in diagnosing the degree of advancement of osteoarthritis of an individual and in the identification of novel therapeutic targets for OA. The invention further provides for the use of these sequences as a tool to diagnose disease progression and to monitor the efficacy of therapeutic regimens.

Abstract: The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in individuals with mild osteoarthritis as compared with individuals without osteoarthritis. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in diagnosing mild osteoarthritis. Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and/or selectively hybridize to the product of the biomarkers of the invention to monitor disease regression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis.

Abstract: Methods and compositions for nucleic acid amplification, detection, and genotyping techniques are disclosed. In one embodiment, a nucleic acid molecule having a target-specific primer sequence; an anti-tag sequence 5? of the target-specific primer sequence; a tag sequence 5? of the anti-tag sequence; and a blocker between the anti-tag sequence and the tag sequence is disclosed. Compositions containing such a nucleic acid molecule and methods of using such a nucleic acid molecule are also disclosed.

Abstract: The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in osteoarthritis and/or in a particular stage of osteoarthritis, as well as a means of selecting the novel biomarker combinations. The measurement of expression of the products of the biomarkers and combinations of biomarkers of the invention demonstrates particular advantage in one or more of the following: (a) diagnosing individuals as having arthritis, (b) differentiating between two stages of osteoarthritis (OA) and (c) diagnosing individuals as having a particular stage of osteoarthritis (OA).

Abstract: The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in individuals with mild osteoarthritis as compared with individuals without osteoarthritis. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in diagnosing mild osteoarthritis. Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and/or selectively hybridize to the product of the biomarkers of the invention to monitor disease regression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis.

Abstract: In one aspect the invention is a method of testing for one or more colorectal pathologies or one or more subtypes of colorectal pathology (in one embodiment colorectal cancer) in a test individual by providing data corresponding to a level of products of selected biomarkers and applying the data to a formula to provide an indication of whether the test individual has one or more colorectal pathologies or one or more subtypes of colorectal pathology. In some aspects the method is computer based and a computer applies the data to the formula. In other aspects a computer system is configured with instructions that cause the processor to provide a user with the indication of whether the test individual has colorectal pathology. Also encompassed are kits for measuring data corresponding to the products of selected biomarkers which in some embodiments include a computer readable medium. Also encompassed are kits and methods of monitoring therapeutic efficacy of treatments for one or more colorectal pathologies.